Bayer has announced its intention to invest $150m in the construction of a cell culture technology facility at its pharmaceutical development and manufacturing site in Berkeley, California.
The Cell Center Technology Center will support Bayer's biologics portfolio and aim to accelerate the development of biological therapies. Built on Bayer's Berkeley campus, the 40,000 square foot facility, has been scheduled to begin clinical production in late-2021 and will have an emphasis on oncology, cardiology and additional specialty care therapeutic areas.
Wolfram Carius, executive vice-president and head of Bayer Pharmaceuticals Product Supply, said: "This investment allows Bayer to expand our biologics development and launch capabilities, as we advance our R&D programs internally and through strategic collaborations.
"We are especially proud to bring this investment to Berkeley, where Bayer has been for many years, and to the greater San Francisco Bay Area, the birthplace of biotechnology and a global epicenter of drug development innovation."
Bayer has partnered with both Fluor and GE Healthcare on the Cell Culture Technology Center and will tap into their expertise in designing flexible and scalable facilities. GE Healthcare's FlexFactory technology platform is set to be integrated at the facility.
Judy Chou, senior vice-president and global head of Bayer Biotech, remarked: "Bayer's Cell Center Technology Center will combine automation, digital capabilities and single-use bioprocessing technologies to streamline production to allow us to bring new medicines to patients faster."